Department of Psychology, Syracuse University, Syracuse University, Syracuse, NY, USA.
Behavioral Medicine Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
AIDS Care. 2020 Oct;32(10):1251-1257. doi: 10.1080/09540121.2020.1770671. Epub 2020 Jun 1.
Although there is evidence of individual associations between depressive symptoms and hazardous alcohol use with suboptimal antiretroviral therapy (ART) adherence among people living with HIV (PLWH), few studies have established how the two risk factors may interact to predict viral suppression. We conducted secondary data analyses with two cohorts of Ugandan PLWH ( = 657) to investigate the hypothesized interaction between depressive symptoms (Center for Epidemiological Studies Depression Scale) and hazardous alcohol use (Alcohol Use Disorder Identification Test -Consumption and/or Phosphatidylethanol biomarker) prior to ART initiation with viral suppression (<550 copies/ml). We were unable to detect an interaction between depressive symptoms and hazardous alcohol use prior to ART initiation with viral suppression in the first two years ( = 19.9 months) after ART initiation ( = 0.75). There was also no evidence of a main effect association for depressive symptoms (Adjusted Odds Ratio [AOR] = 0.88, 95% Confidence Interval [CI]: 0.50, 1.55) or hazardous alcohol use (AOR = 1.37, 95% CI: 0.80, 2.33). PLWH with depressive symptoms and/or hazardous alcohol use appear to exhibit similar levels of viral suppression as others in care; further work is needed to determine effects on HIV testing and treatment engagement.
虽然有证据表明,在感染艾滋病毒的人群(PLWH)中,抑郁症状和危险饮酒与接受抗逆转录病毒治疗(ART)的依从性不佳之间存在个体关联,但很少有研究确定这两个风险因素如何相互作用以预测病毒抑制。我们对乌干达的两个 PLWH 队列(= 657)进行了二次数据分析,以调查在开始接受 ART 之前(= 19.9 个月),抑郁症状(流行病学研究中心抑郁量表)和危险饮酒(酒精使用障碍识别测试-消耗和/或磷脂酰乙醇生物标志物)与开始接受 ART 后两年内的病毒抑制(<550 拷贝/ml)之间假设的相互作用。在开始接受 ART 后的头两年内(= 19.9 个月),我们未能检测到开始接受 ART 前的抑郁症状和危险饮酒与病毒抑制之间的相互作用(= 0.75)。此外,抑郁症状(调整后的优势比 [AOR] = 0.88,95%置信区间 [CI]:0.50,1.55)或危险饮酒(AOR = 1.37,95%CI:0.80,2.33)均无主要关联证据。有抑郁症状和/或危险饮酒的 PLWH 似乎与其他接受治疗的人具有相似的病毒抑制水平;需要进一步的工作来确定对 HIV 检测和治疗参与的影响。